

Supplementary Table S3. Quality evaluation of the eligible studies with Newcastle-Ottawa scale.

Study	Selection			Comparability			Outcome		
	Representative-ness	Selection of non-exposed	Ascertainment of exposure	Outcome not present at start	Comparability on most important factors	Comparability on other risk factors	Assessment of outcome	Long enough follow-up (median $\geq$ 1 year)	Adequacy (completeness) of follow-up
Neumann, 2023 (36)	*	*	*	*	-	-	*	*	-
Kubota 2022 (35)	-	*	*	*	*	-	*	*	*
Ueberroth 2021 (34)	-	-	*	*	*	-	*	*	*
Markus, 2021 (33)	-	*	*	*	-	-	*	*	*
Fang, 2021 (32)	-	*	*	*	*	-	*	*	*
Zhou 2020 (31)	-	*	*	*	*	-	*	*	*
Takeuchi 2020 (30)	-	*	*	*	*	-	*	*	*
Takano 2020 (29)	-	*	*	*	*	-	*	*	*
Pointer 2020 (28)	-	*	*	*	*	-	*	*	*
Onoe 2019 (27)	-	*	*	*	-	-	*	*	*
Kawai 2019 (26)	-	*	*	*	*	-	*	-	*
Sierzeza 2017 (25)	-	*	*	*	-	-	*	*	-
Li 2016 (24)	*	*	*	*	*	-	*	*	*
Stotz 2015 (23)	-	*	*	*	-	-	*	*	*

*indicates criterion met; - indicates significant of criterion not met.